Journal List > J Lung Cancer > v.8(2) > 1050712

Kim, Park, and Wang: Immunohistochemical Assessment of Peripheral Squamous Lung Cancer: Comparison to Central Squamous Cell Carcinoma and Peripheral Adenocarcinoma



Incidence of peripheral squamous cell carcinoma (pSCCs) of the lung has increased over recent years, but the immunohistochemical factors involved in pSCCs have not been well established. The aim of this study was to analyze the immunohistochemical differences between pSCCs and central-type SCCs (cSCCs), and similarities between pSCCs and peripheral adenocarcinomas (pADCs).

Materials and Methods

In this retrospective study, we investigated the expression of three potential prognostic factors (p53, Ki-67, t-CEA), and two potential therapeutic targets (epidermal growth factor receptor [EGFR], and c-erbB-2) in 263 surgically resected cases of primary SCC and pADCs of the lung from January 2001 to July 2008. We divided the SCCs between peripheral and central types, and compared the expression rates of markers between pSCCs and cSCCs, and between pSCCs and pADCs.


In this study, there were 149 pADC cases, and among the 114 SCC cases, there were 41 pSCCs (36.0%). There were significantly higher expression rates of Ki-67 and EGFR in pSCCs than in cSCCs or pADCs (p=0.003, p=0.039, respectively).


We found immunohistochemical differencies in pSCCs from cSCCs and pADCs.


1. Hammar SP, Brambilla E, Pugatch B, et al. Squamous cell carcinoma. Travis WD, Brambilla E, Muller-hermelink HK, Harris CC, editors. Pathology and genetics of tumours of the lung, pleura, thymus, and heart. Lyon: IARC Press;2004. p. 26–30.
2. Asamura H, Nakayama H, Kondo H, Tsuchiya R, Shimosato Y, Naruke T. Lymph node involvement, recurrence, and prognosis in resected small, peripheral, nonsmall-cell lung carcinomas: are these carcinomas candidates for video-assisted lobectomy? J Thorac Cardiovasc Surg. 1996; 111:1125–1134.
3. Tomasshefski JF Jr, Connors AF Jr, Rosenthal ES, Hsiue IL. Peripheral vs central squamous cell carcinoma of the lung. A comparison of clinical features, histopathology, and survival. Arch Pathol Lab Med. 1990; 114:468–474.
4. Funai K, Yokose T, Ishii G, et al. Clinicopathologic characteristics of peripheral squamous cell carcinoma of the lung. Am J Surg Pathol. 2003; 27:978–984.
5. Kushihashi T, Munechika H. Histologic classification and radiologic manefestation of lung cancer. Jpn J Diagn Imaging. 1994; 16:379–390.
6. Takahasi T. Squamous cell carcinomas in the periphery of the lung: cell types and roentgenological findings. Jpn J Lung Cancer. 1984; 24:183–194.
7. Zwirewich CV, Vedal S, Miller RR, Mü ller NL. Solitary pulmonary nodule: high-resolution CT and radiologic-pathologic correlation. Radiology. 1991; 179:469–476.
8. el-Torkey M, Giltman LI, Dabbous M. Collagens in scar in carcinoma of the lung. Am J Pathol. 1985; 121:322–326.
9. Tokuda H. Morphological features of peripherally originating squamous cell carcinoma of the lung. Jpn J Lung Cancer. 1990; 30:963–973.
10. Sakurai H, Asamura H, Watanabe S, Suzuki K, Tsuchiya R. Clinicopathologic features of peripheral squamous cell carcinoma of the lung. Ann Thorac Surg. 2004; 78:222–227.
11. Demoly P, Pujol JL, Godard P, Michel FB. Oncogenes and anti-oncogenes in lung cancer. Presse Med. 1994; 23:291–297.
12. Salgia R, Skarin AT. Molecular abnormalities in lung cancer. J Clin Oncol. 1998; 16:1207–1217.
13. Osada H, Takahashi T. Pathophysiology of lung cancer. Saishin Igaku. 1997; 52:12–18.
14. Harpole DH Jr, Richards WG, Herndon JE 2nd, Sugarbaker DJ. Angiogenesis and molecular biologic substaging in patients with stage I nonsmall cell lung cancer. Ann Thorac Surg. 1996; 61:1470–1476.
15. Sadoff L. The usefulness of carcinoembryonic antigen testing in the overall management of patients with nonsmall cell lung cancer. Am J Clin Oncol. 1998; 21:284–286.
16. Veronesi G, Pelosi G, Sonzogni A, et al. Tumour CEA as predictor of better outcome in squamous cell carcinoma of the lung. Lung Cancer. 2005; 48:233–240.
17. Kern JA, Filderman AE. Oncogenes and growth factors in human lung cancer. Clin Chest Med. 1993; 14:31–41.


Table 1.
Group Cytology n (%)
  Squamous cell carcinoma 114
I pSCCs 41 (36%)
II cSCC 73 (64%)
  Adenocarcinoma 149
III pADCs 149 (100%)
Total   263

pSCCs: peripheral squamous cell carcinomas, cSCCs: central squamous cell carcinomas, pADCs: peripheral adenocarcinomas

Table 2.
Positive Rates of Various Tumor Markers and Statistical Differences among the Groups
Tumor markers Cytology Positive rate (%)  
p53 pSCCs 63  
  cSCCs 54 p=0.301
  pADCs 41 p=0.062
Ki-67 pSCCs 93  
  cSCCs 75 p=0.077
  pADCs 55 p=0.003
t-CEA pSCCs 70  
  cSCCs 70 p=0.500
  pADCs 81 p=0.223
EGFR pSCCs 100  
  cSCCs 71 p=0.039
  pADCs 80 p=0.074
c-erbB-2 pSCCs 31  
  cSCCs 50 p=0.137
  pADCs 45 p=0.178

EGFR: epidermal growth factor receptor

Similar articles